Usefulness of Rosuvastatin to Prevent Periprocedural Myocardial Injury in Patients Undergoing Elective Coronary Intervention

Takano, Hitoshi; Ohba, Takayoshi; Yamamoto, Etsuhide; Miyachi, Hideki; Inui, Kentaro; Kawanaka, Hidekazu; Kamiya, Mamoru; Kikuchi, Arifumi; Takahashi, Yasuhiro; Tanabe, Jun; Inami, Shigenobu; Takagi, Gen; Asai, Kuniya; Yasutake, Masahiro; Ibuki, Chikao; Tanaka, Kunio; Kusama, Yoshiki; Seino, Yoshihiko; Munakata, Kazuo; Mizuno, Kyoichi

doi:10.1016/j.amjcard.2013.02.018

Cited by 21 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated that rosuvastatin exert versatile changes in inflammatory cells such as reduction of cytokines and adhesion molecules on isolated cells, animal models, and patients with ACS . Their benefit has also been largely demonstrated in the setting of PCI by the prevention of PMI . Although recent randomized controlled trials have confirmed that high loading dose of a statin before PCI reduces PMI, most of these studies were conducted using atorvastatin .…”

Section: Discussionmentioning

confidence: 99%

“…Percutaneous coronary intervention was performed immediately after diagnostic angiography. Angiographic success was defined as angiographic residual stenosis <30% by visual estimate or quantitative coronary angiography with optimized angiographic flow (thrombolysis in myocardial infarction grade III) . Aspirin (100 mg/day), clopidogrel (75 mg/day), and rosuvastatin (10 mg/day) were prescribed to all patients after the procedure.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR‐155/SHIP‐1 Signaling Pathway

Xie

Wang

et al. 2014

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYPurpose: The beneficial effect of rosuvastatin against percutaneous coronary intervention (PCI) related procedural myocardial injury has been determined mostly in patients with acute coronary syndromes (ACS). However, the detailed therapeutic mechanism has not been well studied. Treg percentage values (P < 0.05). In addition, patients with rosuvastatin pretreatment also reduced incidence of 30 days major adverse cardiac events (MACE) compared to the patients with placebo treatment (16 patients vs. 28 patients, P = 0.038). Conclusions: Our study suggests that high loading dose rosuvastatin pretreatment may reduce the incidence of cardiovascular events and levels of inflammatory markers in patients with ACS receiving PCI, which may be explained at least in part, by mechanism involving suppression of miR-155/SHIP-1 signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR‐155/SHIP‐1 Signaling Pathway

Xie

Wang

et al. 2014

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…On the contrary, in the ROMA trial, high loading dose of rosuvastatin (40 mg) within 24 h before elective PCI decreased the incidence of periprocedural MI compared to the standard treatment [29]. Furthermore, Takano et al [30] reported that the incidence of periprocedural MI was reduced more effectively by high-dose than by low-dose rosuvastatin in statin-näive patients. 2) Can a dose of rosuvastatin, more potent in terms of LDL cholesterol reduction and HMG-CoA reductase inhibition, further improve on the results of the ARMYDA-ACS study [8]?…”

Section: Discussionmentioning

confidence: 95%

“…Sampling at 48 h will be optional, in case of abnormal markers in previous samples. Measurements of CK-MB mass and/or TnI or TnT will be performed locally [30]. Upper normal limits are defined as the 99th percentiles of the normal population, with a total imprecision of <10 %, according to the Joint European Society of Cardiology/American College of Cardiology guidelines [31].…”

Section: Biochemical Parametersmentioning

confidence: 99%

Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial

Briguori

Madonna

Zimarino

et al. 2016

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

The REMEDY study will enroll a total of 1080 patients submitted to elective PCI. Eligible patients will be randomized into 4 groups: 1) placebo; 2) atorvastatin (80 mg + 40 mg before PCI); 3) rosuvastatin (40 mg twice before PCI); and 4) rosuvastatin (5 mg) and ezetimibe (10 mg) twice before PCI. Peri-procedural MI is defined as an elevation of markers of cardiac injury (either CK-MB or troponin I or T) values >5x the upper reference limit estimated at the 99th percentile of the normal distribution, or a rise >20 % in case of baseline values already elevated. EPCs will be assessed before, at 24 h and - in a subset of diabetic patients - at 3 months after PCI (EPC-substudies). The primary endpoint of the main REMEDY study is the rate of peri-procedural MI in each of the 4 treatment arms. Secondary endpoints are the combined occurrence of 1-month major adverse events (MACE, including death, MI, or the need for unplanned revascularization); and any post-procedural increase in serum creatinine. Endpoints of the EPC-substudies are the impact of tested regimens on 1) early (24-h) and 3-month EPC levels and functional activity; 2) stent strut re-endothelialization and neointimal hyperplasia; 3) 1-year MACE. REMEDY will add important information on the cardioprotective effects of statins after PCI.

show abstract

“…According to our standard protocol and previous report [5], all patients without contraindications were administered aspirin (100 mg/day) and ticlopidine (100 mg B.I.D.) for at least 7 days before the procedure.…”

Section: Methodsmentioning

confidence: 99%

Geographical predisposition influences on the distribution and tissue characterisation of eccentric coronary plaques in non-branching coronary arteries: cross-sectional study of coronary plaques analysed by intravascular ultrasound

Komiyama

Takano

Nakamura

et al. 2016

Cardiovasc Ultrasound

Self Cite

View full text Add to dashboard Cite

BackgroundWe investigated the influence of geographical predisposition on the spatial distribution and composition of coronary plaques.MethodsThirty coronary arteries were evaluated. A total of 1441 cross-sections were collected from intravascular ultrasound (IVUS) and radio-frequency signal-based virtual histology (VH-IVUS) imaging. To exclude complex geographical effects of side branches and to localise the plaque distribution, we analysed only eccentric plaques in non-branching regions. The spatial distribution of eccentric plaques in the coronary artery was classified into myocardial, lateral, and epicardial regions. The composition of eccentric plaques was analysed using VH-IVUS.ResultsThe plaque was concentric in 723 sections (50.2%) and eccentric in 718 (49.9%). Eccentric plaques were more frequently distributed towards the myocardial side than towards the epicardial side (46.7 ± 7.5% vs. 12.5 ± 4.2%, p = 0.003). No significant difference was observed between the myocardial and lateral sides (46.7 ± 7.5% vs. 20.8 ± 5.0%) or between the lateral and epicardial sides. Eccentric thin-capped fibroatheromas were more frequently distributed towards the myocardial side than towards the lateral side (p = 0.024) or epicardial side (p = 0.005).ConclusionGeographical predisposition is associated with distribution, tissue characterisation, and vulnerability of plaques in non-branching coronary arteries.

show abstract

Usefulness of Rosuvastatin to Prevent Periprocedural Myocardial Injury in Patients Undergoing Elective Coronary Intervention

Cited by 21 publications

References 26 publications

Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR‐155/SHIP‐1 Signaling Pathway

Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR‐155/SHIP‐1 Signaling Pathway

Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial

Geographical predisposition influences on the distribution and tissue characterisation of eccentric coronary plaques in non-branching coronary arteries: cross-sectional study of coronary plaques analysed by intravascular ultrasound

Contact Info

Product

Resources

About